New One-Dose Therapy Could Cure Autoimmune Diseases

For patients battling autoimmune diseases, the daily reality means endless pills, regular infusions, and a lifetime of managing symptoms that never truly disappear. A Cambridge biotech company is working to change that story completely.

Sail Biomedicines will present preclinical data this May showing their revolutionary approach works: a single IV infusion that turns a patient's own immune cells into disease fighters without ever removing them from the body. Unlike current CAR-T therapies that require extracting cells, engineering them in a lab, and infusing them back in a process costing hundreds of thousands of dollars, Sail's method does everything in one shot.

The therapy targets the root cause of many autoimmune diseases. Rogue B-cells attack healthy tissue in conditions like lupus and multiple sclerosis, forcing patients onto immune-suppressing drugs that leave them vulnerable to infections. Sail's treatment programs T-cells to hunt down and eliminate these problem cells, allowing the immune system to rebuild itself in a healthy, balanced state.

The science behind it solves two major challenges that have held back gene therapy. First, Sail uses circular RNA instead of the linear kind, which breaks down quickly in the body. This circular structure resists degradation, creating longer-lasting effects from smaller doses.

Second, their specially designed nanoparticles act like precision-guided delivery trucks. These microscopic particles seek out specific immune cells, deliver their genetic instructions, and transform regular T-cells into therapeutic CAR-T cells right where they're needed. No viruses required, which means fewer safety risks.

"The power of In Vivo CAR-T for curative treatments in autoimmune diseases could completely disrupt treatment paradigms for patients," said John Mendlein, Executive Chairman of Sail Biomedicines. The company aims for what they call a "full immune reset."

Sail isn't the only company chasing this breakthrough. Competitors like Capstan Therapeutics and Umoja Biopharma are developing similar approaches, while gene-editing pioneers like Intellia Therapeutics have already proven in-vivo delivery works for other diseases. This collective pursuit signals something important: the scientific community believes curing autoimmune disease is no longer a distant dream.

The upcoming conferences will reveal crucial details about safety, effectiveness, and how long the treatment lasts. These answers will determine whether millions of patients can finally imagine life beyond symptom management.

Why This Inspires

The real power of this research goes beyond the impressive science. It represents a fundamental shift in how we think about chronic disease. For decades, autoimmune patients have been told to manage their conditions, not cure them. This work challenges that assumption at its core.

Backed by Flagship Pioneering, the venture firm behind Moderna, Sail brings both cutting-edge science and serious resources to a problem affecting millions worldwide. The approach could work for multiple autoimmune conditions, multiplying its potential impact exponentially.

One treatment replacing a lifetime of medication means freedom: freedom from side effects, from constant medical appointments, from planning life around disease management. That possibility alone is worth celebrating.